LGC's pharmaceutical services division has announced promising results from two of its current research programmes.
Highlighting LGC's increased commitment to the pharmaceutical and biotechnology sectors, the company's new pharmaceutical services division has announced promising results from two of its current research programmes.
The initial results of a joint research venture between LGC and King's College, London (KCL) point the way ahead for a promising in vitro prediction model of blood-brain barrier penetration for early drug screening.
The research, which is being carried out at KCL, with support from LGC, could improve the selection of new drug candidates.
In a separate study, LGC has defined new methods to improve both the practical approach and measurement accuracy when considering extractables from the plastic materials used in packaging and/or delivering pharmaceutical products.
Derek Craston, head of LGC's Pharmaceutical Services, said: "LGC is committed to good measurement practice to improve analytical data and results for the pharmaceutical and biotechnology industries.
These latest research results reflect the diverse range of specialist services and products that LGC now offers companies in these sectors.
The increase in competitive pressures and the need to focus resources have meant that external providers such as LGC now deliver many of the non-core elements of a company's business.
We have expanded our offerings to support relevant areas of the drug discovery and development process, which we can tailor to help customers accelerate new product pipelines and regulatory approval." LGC's new research results were exhibited as posters at this year's British Pharmaceutical Conference (BPC) in Harrogate (15-17 September 2003).
Its range of pharmaceutical services, also showcased at BPC, comprise: a comprehensive stock of chemical compounds for library production or activity screening; in vitro ADME-Tox screening for potential drug candidates; custom compound synthesis and consultancy service; the supply of high quality pharmaceutical actives, impurities and metabolites; leachables and extractables testing; product characterisation and analytical problem solving; analytical research, method development and validation; pharmacogenetic testing and DNA banking services.
